EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) - revised report of an EFNS task force

European Journal of Neurology

Volumn 19, Issue 3, 2012, Pages 360-375

  Andersen, Peter M ^a   Abrahams, Sharon ^b   Borasio, Gian D ^c   de Carvalho, Mamede ^d   Chio, Adriano ^e   Van Damme, Philip ^f   Hardiman, Orla ^g   Kollewe, Katja ^h   Morrison, Karen E ⁱ   Petri, Susanne ^h   Pradat, Pierre Francois ^j   Silani, Vincenzo ^k   Tomik, Barbara ^l   Wasner, Maria ^m   Weber, Markus ⁿ  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h HANNOVER MEDICAL SCHOOL   (Germany)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k UNIVERSITY OF MILAN   (Italy)

^l JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ UNIVERSITY HOSPITAL BASEL   (Switzerland)

more..

Author keywords

ALS; Breaking the diagnosis; Bronchial secretions; Caregiver; Cognitive dysfunction; Drooling; Evidence based medicine; Genetic counselling; Nutrition; Palliative care; Terminal care; Ventilation

Indexed keywords

ACETYLCYSTEINE; AMITRIPTYLINE; ATROPINE; BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CARBAMAZEPINE; DANTROLENE; DEXTROMETORPHAN PLUS QUINIDINE; DIAZEPAM; ESCITALOPRAM; ETIRACETAM; FUROSEMIDE; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; GUAIFENESIN; IPRATROPIUM BROMIDE; MEMANTINE; METOPROLOL; PHENYTOIN; PROPRANOLOL; QUININE SULFATE; RILUZOLE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR; TETRAZEPAM; THEOPHYLLINE; TIZANIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; AMYOTROPHIC LATERAL SCLEROSIS; ANXIETY DISORDER; ARTICLE; BLADDER DYSFUNCTION; BLOOD EXAMINATION; BRONCHUS SECRETION; CAREGIVER SUPPORT; CEREBROSPINAL FLUID ANALYSIS; COCHRANE LIBRARY; COGNITION; COLD TREATMENT; COMPRESSION GARMENT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; EARLY DIAGNOSIS; ELECTROMYOGRAPHY; ELECTROSTIMULATION; EMBASE; ENTERIC FEEDING; EXERCISE; FATIGUE; GENETIC COUNSELING; GENETIC SCREENING; HEAT TREATMENT; HUMAN; HYDROTHERAPY; HYPERSALIVATION; INSOMNIA; INTERPERSONAL COMMUNICATION; IRRADIATION; LIVING WILL; MAMMOGRAPHY; MASSAGE; MEDLINE; MENTAL INSTABILITY; MUSCLE CRAMP; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARKINSON DISEASE; PATIENT AUTONOMY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHASE 4 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; POSITIVE END EXPIRATORY PRESSURE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SCISEARCH; SPASTICITY; STOMACH TUBE; STRIDOR; SURVIVAL; SYSTEMATIC REVIEW; TERMINAL CARE; THORAX RADIOGRAPHY; TRISMUS; ULTRASOUND; URINALYSIS;

ADVISORY COMMITTEES; AMYOTROPHIC LATERAL SCLEROSIS; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84857044928     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2011.03501.x     Document Type: Article

References (186)

1. Andersen PM, Borasio GD, Dengler R, et al. EFNS Task Force on Management of Amyotrophic Lateral Sclerosis. Guidelines for diagnosing and clinical care of patients and relatives. An evidence-based review with Good Practice Points. Eur J Neurol 2005; 12: 921-938.
2. Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand 1983; 68: 20-29.
3. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995; 118: 707-719.
4. Scott KM, Abhinav K, Stanton BR, et al. Geographical clustering of amyotrophic lateral sclerosis in South-East England: a population study. Neuroepidemiology 2009; 32: 81-88.
5. Alonso A, Logroscino G, Jick SS, Hernán MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 2009; 10: 745-751.
6. Brainin M, Barnes M, Baron J-C, et al. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces - revised recommendations 2004. Eur J Neurol 2004; 11: 577-581.
7. Li TM, Day SJ, Alberman E, Swash M. Differential diagnosis of motoneurone disease from other neurological conditions. Lancet 1986; 2: 731-733.
8. Wilbourn AJ. Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria. J Neurol Sci 1998; 160(Suppl. 1): S25-S29.
9. Meininger V. Getting the diagnosis right: beyond El Escorial. J Neurol 1999; 246(Suppl. 3): III10-III15.
10. Rosen AD. Amyotrophic lateral sclerosis. Clinical features and prognosis. Arch Neurol 1978; 35: 638-642.
11. Chio A, Mora G, Calvo A, et al. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009; 72: 725-731.
12. Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. Neurologist 1999; 5: 63-74.
13. Aggarwal A, Nicholson G. Detection of preclinical motor neurone loss in SOD1 mutation carriers using motor unit number estimation. J Neurol Neurosurg Psychiatry 2002; 73: 199-201.
14. Brooks BR. Diagnostic dilemmas in amyotrophic lateral sclerosis. J Neurol Sci 1999; 165(Suppl 1): S1-S9.
15. Evangelista T, Carvalho M, Conceicao I, Pinto A, de Lurdes M, Luis ML. Motor neuropathies mimicking amyotrophic lateral sclerosis/motor neuron disease. J Neurol Sci 1996; 139(Suppl.): 95-98.
16. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes. Arch Neurol 2000; 57: 109-113.
17. Belsh JM, Schiffman PL. The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions. J Neurol Sci 1996; 139(Suppl.): 110-116.
18. Davenport RJ, Swingler RJ, Chancellor AM, Warlow CP. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J Neurol Neurosurg Psychiatry 1996; 60: 147-151.
19. Brooks BR. Earlier is better: the benefits of early diagnosis. Neurology 1999; 53(Suppl. 5): S53-S54.
20. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.
21. Ross MA, Miller RG, Berchert L, et al. Towards earlier diagnosis of ALS. Revised criteria. Neurology 1998; 50: 768-772.
22. Carvalho M, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler 2009; 10: 53-57.
23. Douglass CP, Kandler RH, Shaw PJ, McDermott CJ. An evaluation of neurophysiological criteria used in the diagnosis of motor neurone disease. J Neurol Neurosurg Psychiatry 2010; 81: 646-649.
24. Okita T, Nodera H, Shibuta Y, et al. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? J Neurol Sci 2011; 302: 29-32.
25. Boekestein WA, Kleine BU, Hageman G, Schelhaas HJ, Zwarts MJ. Sensitivity and specificity of the 'Awaji' electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALS. Amyotroph Lateral Scler 2010; 11: 497-501.
26. Chen A, Weimer L, Brannagan T, et al. Experience with the Awaji Island modifications to the ALS diagnostic criteria. Muscle Nerve 2010; 42: 831-832.
27. Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol 2011; 70: 79-83.
28. Leigh PN, Abrahams S, Al-Chalabi A, et al. The management of motor neuron disease. J Neurol Neurosurg Psychiatry 2003; 70(Suppl. IV): iv32-iv47.
29. Borasio GD, Sloan R, Pongratz DE. Breaking the news in amyotrophic lateral sclerosis. J Neurol Sci 1998; 160(Suppl. 1): S127-S133.
30. McCluskey L, Casarett D, Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 131-135.
31. Davies E, Hopkins A. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working Group. Br J Neurosurg 1997; 11: 318-330.
32. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009; 73: 1227-1233.
33. Borasio GD, Shaw PJ, Hardiman O, et al. Standards of palliative care for patients with amyotrophic lateral sclerosis: results of a European survey. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 159-164.
34. Ackerman GM, Oliver D. Psychosocial support in an outpatient clinic. Palliat Med 1997; 11: 167-168.
35. Howard RS, Orrell RW. Management of motor neurone disease. Postgrad Med J 2002; 78: 736-741.
36. Chio A, Bottacchi E, Buffa C, Mutani R, Mora G. Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006; 77: 948-950.
37. Sorenson EJ, Mandrekar J, Crum B, Stevens JC. Effect of referral bias on assessing survival in ALS. Neurology 2007; 68: 600-602.
38. Traynor BJ, Alexander M, Corr B, et al. Effects of a multidisciplinary ALS clinic on survival. J Neurol Neurosurg Psychiatry 2003; 74: 1258-1261.
39. Zoccolella S, Beghi E, Palagano G, et al. ALS multidisciplinary clinic and survival. Results from a population-based study in Southern Italy. J Neurol 2007; 254: 1107-1112.
40. Mayadev AS, Weiss MD, Distad BJ, Krivickas LS, Carter GT. The amyotrophic lateral sclerosis center: a model of multidisciplinary management. Phys Med Rehabil Clin N Am 2008; 19: 619-631.
41. Kareus SA, Kagebein S, Rudnicki SA. The importance of a respiratory therapist in the ALS clinic. Amyotroph Lateral Scler 2008; 9: 173-176.
42. Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005; 65: 1264-1267.
43. Corr B, Frost E, Traynor BJ, Hardiman O. Service provision for patients with ALS/MND: a cost-effective multidisciplinary approach. J Neurol Sci 2008; 160(Suppl. 1): S141-S145.
44. Chiò A, Gauthier A, Vignola A, et al. Caregiver time use in ALS. Neurology 2006; 67: 902-904.
45. Hecht MJ, Graesel E, Tigges S, et al. Burden of care in amyotrophic lateral sclerosis. Palliat Med 2003; 17: 327-333.
46. Gauthier A, Vignola A, Calvo A, et al. A longitudinal study on quality of life and depression in ALS patient-caregiver couples. Neurology 2007; 68: 923-926.
47. Gelinas DF, O'Connor P, Miller RG. Quality of life for ventilator-dependent ALS patients and their caregivers. J Neurol Sci 1998; 160(Suppl. 1): S134-S136.
48. Kaub-Wittemer D, Steinbüchel N, Wasner M, Laier-Groeneveld G, Borasio GD. Quality of life and psychosocial issues in ventilated patients with amyotrophic lateral sclerosis and their caregivers. J Pain Symptom Manage 2003; 26: 890-896.
49. Mustfa N, Walsh E, Bryant V, et al. The effect of noninvasive ventilation on ALS patients and their caregivers. Neurology 2006; 66: 1211-1217.
50. Wasner M, Bold U, Vollmer TC, Borasio GD. Sexuality in patients with amyotrophic lateral sclerosis and their partners. J Neurol 2004; 251: 445-448.
51. Neudert C, Oliver D, Wasner M, Borasio GD. The course of the terminal phase in patients with amyotrophic lateral sclerosis. J Neurol 2001; 248: 612-616.
52. Hebert RS, Lacomis D, Easter C, Frick V, Shear MK. Grief support for informal caregivers of patients with ALS: a national survey. Neurology 2005; 64: 137-138.
53. Paz-Rodriguez F, Andrade-Palos P, Llanos-Del Pilar AM. Emotional consequences of providing care to amyotrophic lateral sclerosis patients. Rev Neurol 2005; 40: 459-464.
54. Martin J, Turnbull J. Lasting impact in families after death from ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2: 181-187.
55. Bensimon G, Lacomblez L, Meininger V, et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591.
56. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-1431.
57. Yanagisawa N, Tashiro K, Toghi T, et al. Efficacy and safety f riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan. Igakuno Ayumi 1997; 182: 851-866.
58. Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609-615.
59. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007; 2: CD001447.
60. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with ALS treated with riluzole. Arch Neurol 1998; 55: 526-528.
61. Mitchell JD, O'Brien MR, Joshi M. Audit of outcomes in motor neuron disease (MND) patients treated with riluzole. Amyotroph Lateral Scler 2006; 7: 67-71.
62. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. An outcome study of riluzole in amyotrophic lateral sclerosis - a population-based study in Ireland, 1996-2000. J Neurol 2003; 250: 473-479.
63. Brooks BR, Belden DS, Roelke K, et al. Survival in non-riluzole treated ALS patients is identical before and since 1996: a clinic-based epidemiological study. Amyotroph Lateral Scler Other Motor Neuron Disord 2001; 2(Suppl. 2): 60-61. (Abstract #P15).
64. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002; 3: 15-21.
65. Andersen PM, Sims KB, Xin WW, et al. Sixteen novel mutations in the gene encoding CuZn-superoxide dismutase in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 2: 62-73.
66. Forshew DA, Bromberg MB. A survey of clinicians' practice in the symptomatic treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 258-263.
67. Arbouw ME, Movig KL, Koopmann M, et al. Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74: 1203-1207.
68. Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary flow in amyotrophic lateral sclerosis with scopoderm TTS. Head Neck 1989; 11: 565.
69. Talmi YP, Finkelstein Y, Zohar Y. Reduction of salivary flow with transdermal scopolamine: a four-year experience. Otolaryngol Head Neck Surg 1990; 103: 615-618.
70. Giess R, Naumann M, Werner E, et al. Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 121-123.
71. Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61: 1279-1281.
72. Gilio F, Iacovelli E, Frasca V, et al. Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study. Amyotroph Lateral Scler 2010; 11: 359-363.
73. Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39: 137-143.
74. Winterholler MG, Erbguth FJ, Wolf S, Kat S. Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach. J Neurol Neurosurg Psychiatry 2001; 70: 417-418.
75. Andersen PM, Grönberg H, Funegård U, Franzen L. X-ray radiation of the parotid glands significantly reduces drooling in patients with progressive bulbar palsy. J Neurol Sci 2001; 191: 111-114.
76. Harriman M, Morrison M, Hay J, et al. Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis. J Otolaryngol 2001; 30: 242-245.
77. Stalpers LJ, Moser EC. Results of radiotherapy for drooling in amyotrophic lateral sclerosis. Neurology 2002; 58: 1308.
78. Neppelberg E, Haugen DF, Thorsen L, Tysnes OB. Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis. Eur J Neurol 2007; 14: 1373-1377.
79. Burton MJ. The surgical management of drooling. Dev Med Child Neurol 1991; 33: 1110-1116.
80. Peysson S, Vandenberghe N, Phillit F, et al. Factors predicting survival following noninvasive ventilation in amyotrophic lateral sclerosis. Eur Neurol 2008; 59: 164-171.
81. Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996; 139(Suppl.): 43-44.
82. Hanayama K, Ishikawa Y, Bach JR. Amyotrophic lateral sclerosis: successful treatment of mucous plugging by mechanical insufflation-exsufflation. Am J Phys Med Rehabil 1997; 76: 338-339.
83. Sancho J, Servera E, Diaz J, Marin J. Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004; 125: 1400-1405.
84. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989; 80: 114-117.
85. Palmieri A, Abrahams S, Sorarù G, et al. Emotional lability in MND: relationship to cognition and psychopathology and impact on caregiver. J Neurol Sci 2009; 278: 16-20.
86. Szczudlik A, Slowik A, Tomik B. The effect of amitriptyline on the pathological crying and other pseudobulbar signs. Neurol Neurochir Pol 1995; 29: 663-674.
87. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996; 19: 532-535.
88. Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. The AVP-923 ALS Study Group. Neurology 2004; 63: 1364-1370.
89. Pioro ET, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010; 68: 693-702.
90. Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry 2010; 81: 1135-1140.
91. Bedlack RS, Pastula DM, Hawes J, Heydt D. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler 2009; 10: 210-215.
92. Katzberg HD, Khan AH, So YT. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2010; 74: 691-696.
93. El-Tawil S, Al Musa T, Valli H, et al. Quinine for muscle cramps. Cochrane Database Syst Rev 2010; 12: CB005044.
94. Drory VW, Goltsman E, Renik JG, et al. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 133-137.
95. Marquardt G, Seifert V. Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2002; 72: 275-276.
96. McClelland S III, Bethoux FA, Boulis NM, et al. Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. Muscle Nerve 2008; 37: 396-398.
97. Winterholler MG, Heckmann JG, Hecht M, Erbguth FJ. Recurrent trismus and stridor in an ALS patient: successful treatment with botulinum toxin. Neurology 2002; 58: 502-503.
98. Vignola A, Guzzo A, Calvo A, et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol 2008; 15: 1231-1236.
99. Wicks P, Abrahams S, Masi D, Hejda-Forde S, Leigh PN, Goldstein LH. Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol 2007; 14: 993-1001.
100. Lou JS. Fatigue in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am 2008; 19: 533-543.
101. Carter GT, Weiss MD, Lou JS, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005; 22: 55-59.
102. Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study. Muscle Nerve 2009; 39: 297-303.
103. Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Venous thrombosis in an ALS population over four years. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 246-249.
104. Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. Neurology 2007; 68: 76-77.
105. Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 2001; 191: 151-154.
106. Mora JS, Munsat TL, Kao KP, et al. Intrathecal administration of natural human interferon alfa in amyotrophic lateral sclerosis. Neurology 1986; 36: 1137-1140.
107. Cudkowicz ME, EWarren L, Francis JW, et al. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study. Neurology 1997; 49: 213-222.
108. Aebischer P, Schluep M, Déglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 2: 696-699.
109. Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 201-206.
110. Nagano I, Shiote M, Murakami T, et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurol Res 2005; 27: 768-772.
111. Finsterer J, Mamoli B. Liquorpheresis (CSF filtration) in familial amyotrophic lateral sclerosis. Spinal Cord 1999; 37: 592-593.
112. Finsterer J, Mamoli B. Cerebrospinal fluid filtration in amyotrophic lateral sclerosis. Eur J Neurol 1999; 6: 597-600.
113. Steele J, Matos LA, Lopez EA, et al. A phase I safety study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 250-254.
114. Steele J, Zutshi D, Bradley WG. Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2007; 8: 274-275.
115. Zanette G, Forgione A, Manganotti P, Fiaschi A, Tamburin S. The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis. J Neurol Sci 2008; 270: 18-22.
116. Di Lazzaro V, Pilato F, Profice P, et al. Motor cortex stimulation for ALS: a double blind placebo-controlled study. Neurosci Lett 2009; 464: 18-21.
117. Janson CG, Ramesh TM, During MJ, Leone P, Heywood J. Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J Hematother Stem Cell Res 2001; 10: 913-915.
118. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008; 265: 78-83.
119. Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008; 71: 1326-1334.
120. Deda H, Inci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy 2009; 11: 18-25.
121. Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy 2009; 11: 26-34.
122. Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol 2010; 223: 229-237.
123. Badayan I, Cudkowicz ME. Is it too soon for mesenchymal stem cell trials in people with ALS? Amyotroph Lateral Scler 2009; 10: 123-124.
124. Huang H, Chen L, Xi H, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant 2008; 22: 710-718.
125. Huang H, Chen L, Xi H, et al. Olfactory ensheathing cells transplantation for central nervous system diseases in 1, 255 patients. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2009; 23: 14-20.
126. Chen L, Huang H, Zhang J, et al. Short-term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 2007; 21: 961-966.
127. Andersen PM, Abrahams S, Borasio GD, et al. Management of amyotrophic lateral sclerosis. In: Gilhus NE, Barnes MP, Brainin M eds. European Handbook of Neurological Management, 2nd edn, vol 1, chapter 17. Chichester: Wiley-Blackwell, 2010: 283-310.
128. Andersen PM, Forsgren L, Binzer M, et al. Autosomal recessive adult-onset ALS associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain 1996; 119: 1153-1172.
129. Jones CT, Swingler RJ, Simpson SA, Brock DJ. Superoxide dismutase mutations in an unselected cohort of Scottish amyotrophic lateral sclerosis patients. J Med Genet 1995; 32: 290-292.
130. Eisen A, Mezei MM, Stewart HG, Fabros M, Gibson G, Andersen PM. SOD1 gene mutations in ALS patients from British Columbia, Canada: clinical features, neurophysiology and ethical issues in management. Amyotroph Lateral Scler 2008; 9: 108-119.
131. Fanos JH, Gronka S, Wuu J, et al. Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genet Med 2011; 13: 342-348.
132. Gil J, Funalot B, Verschueren A. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol 2008; 15: 1245-1251.
133. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001; 124: 2000-2013.
134. Pinto A, de Carvalho M, Evangelista T, Lopes A, Sales-Luis L. Nocturnal pulse oximetry: a new approach to establish the appropriate time for non-invasive ventilation. Amyotroph Lateral Scler 2003; 4: 31-35.
135. Pinto S, Turkman A, Pinto A, Swash M, de Carvalho M. Predicting respiratory insufficiency in amyotrophic lateral sclerosis: the role of phrenic nerve studies. Clin Neurophysiol 2009; 120: 941-946.
136. Sancho J, Servera E, Dias J, Marin J. Prediction of ineffective cough during a chest infection in patients with stable amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2007; 175: 1266-1271.
137. Bourke SC, Gibson GJ. Non-invasive ventilation in ALS: current practice and future role. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 67-71.
138. Mendoza M, Gelinas DF, Moore DH, Miller RG. A comparison of maximal inspiratory and forced vital capacity as potential criteria for initiating non-invasive ventilation in ALS. Amyotroph Lateral Scler 2007; 8: 106-111.
139. Pinto A, Evangelista T, de Carvalho M, Alves MA, Sales-Luis ML. Respiratory assistance with a non-invasive ventilator (BiPAP) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995; 129(Suppl.): 19-26.
140. Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006; 5: 140-147.
141. Lo Cocco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Cocco A. The amyotrophic lateral sclerosis functional rating scale predicts survival time in amyotrophic lateral sclerosis patients on invasive mechanical ventilation. Chest 2007; 132: 64-69.
142. Lechtzin N, Scott Y, Busse AM, Clawson LL, Kimball R, Wiener CM. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph Lateral Scler 2007; 8: 185-188.
143. Onders RP, Carlin AM, Elmo M, Sivashankaran S, Katirii B, Schilz R. Amyotrophic lateral sclerosis: the Midwestern surgical experience with diaphragm pacing stimulation system shows that general anesthesia can be safely performed. Am J Surg 2009; 197: 386-390.
144. Nardin R, O'Donnell C, Loring SH, et al. Diaphragm training in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis 2008; 10: 56-60.
145. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996; 139(Suppl.): 123-128.
146. Miller RG, Jackson CE, Kasarkis EJ, et al. Practise Parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology 2009; 73: 1218-1226.
147. Jennings AL, Davies AN, Higgins JP, Gibbs JS, Broadley KE. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944.
148. Bruera E, Sweeney C, Willey J, et al. A randomized controlled trial of supplemental oxygen versus air in cancer patients with dyspnea. Palliat Med 2003; 17: 659-663.
149. Winck JC, Gonçalves MR, Lourenço C, Viana P, Almeida J, Bach JR. Effects of mechanical insufflation-exsufflation on respiratory parameters for patients with chronic airway secretion encumbrance. Chest 2004; 126: 774-780.
150. Lange DJ, Lechtzin N, Davey C, et al. High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial. Neurology 2006; 67: 991-997.
151. Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 2011; 82: 628-634.
152. Vaisman N, Lusaus M, Nefussy B, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci 2009; 279: 26-29.
153. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 91-96.
154. Heffernan C, Jenkinson C, Holmes T, et al. Nutritional management in MND/ALS patients: an evidence based review. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 72-83.
155. Sancho J, Servera E, Chiner E, et al. Noninvasive respiratory muscle aids during PEG placement in ALS patients with severe respiratory impairment. J Neurol Sci 2010; 297: 55-59.
156. Shaw AS, Ampong MA, Rio A, et al. Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre. Amyotroph Lateral Scler 2006; 7: 16-21.
157. Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994; 40: 463-469.
158. Chio A, Galletti R, Finocchiaro C, et al. Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS. J Neurol Neurosurg Psychiatry 2004; 75: 645-647.
159. Shaw AS, Ampong MA, Rio A, McClure J, Leigh PN, Sidhu PS. Entristar skin-level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. Radiology 2004; 233: 392-399.
160. Thornton FJ, Fotheringham T, Alexander M, Hardiman O, McGrath FP, Lee MJ. Amyotrophic lateral sclerosis: enteral nutrition provision - endoscopic or radiologic gastrostomy? Radiology 2002; 224: 713-717.
161. Blondet A, Lebigot J, Nicholas G, et al. Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy and survival. J Vasc Interv Radiol 2010; 21: 527-533.
162. Scott AG, Austin HE. Nasogastric feeding in the management of severe dysphagia in motor neurone disease. Palliat Med 1994; 8: 45-49.
163. Verschueren A, Monnier A, Attarian S, Lardillier D, Pouget J. Enteral and parenteral nutrition in the later stages of ALS: an observational study. Amyotroph Lateral Scler 2009; 10: 42-46.
164. Abelnour-Mallet M, Verschueren A, Guy N, et al. Safety of home parenteral nutrition in patients with amyotrophic lateral sclerosis: a French national survey. Amyotroph Lateral Scler 2010; 12: 178-184.
165. Gordon PH, Goetz RR, Rabkin JG, et al. A prospective cohort study of neuropsychological test performance in ALS. Amyotroph Lateral Scler 2010; 11: 312-320.
166. Phukan J, Pender N, Hardiman O. Cognitive impairment in ALS. Lancet Neurol 2007; 6: 994-1003.
167. Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011; 76: 1263-1269.
168. Ringholz GM, Appel SH, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005; 65: 586-590.
169. Strong MJ, Grace GM, Freedman M, et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10: 131-146.
170. Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology 2005; 64: 1222-1226.
171. Gibbons ZC, Richardson A, Neary D, Snowden JS. Behaviour in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2008; 9: 67-74.
172. Witgert M, Salamone AR, Strutt AM, et al. Frontal-lobe mediated behavioral dysfunction in amyotrophic lateral sclerosis. Eur J Neurol 2010; 17: 103-110.
173. Gibbons ZC, Snowden JS, Thompson JC, Happe F, Richardson A, Neary D. Inferring thought and action in motor neurone disease. Neuropsychologia 2007; 45: 1196-1207.
174. Girardi A, MacPherson SE, Abrahams S. Deficits in Emotional and Social Cognition in Amyotrophic Lateral Sclerosis. Neuropsychology 2011; 25: 53-65.
175. Abrahams S, Goldstein LH, Suckling J, et al. Frontotemporal white matter changes in amyotrophic lateral sclerosis. J Neurol 2005; 252: 321-331.
176. Donaghy C, Pinnock R, Abrahams S. Ocular fixation instabilities in motor neurone disease. A marker of frontal lobe dysfunction? J Neurol 2009; 256: 420-426.
177. Flaherty-Craig C, Brothers A, Dearman B, Eslinger P, Simmons Z. Penn State screen exam for the detection of frontal and temporal dysfunction syndromes: application to ALS. Amyotrop Lateral Scler 2009; 10: 107-112.
178. Woolley SC, York MK, Moore DH, et al. Detecting frontotemporal dysfunction in ALS: utility of the ALS Cognitive Behavioral Screen (ALS-CBS™). Amyotroph Lateral Scler 2010; 11: 303-311.
179. Gordon PH, Wang Y, Doorish C, et al. A screening assessment of cognitive impairment in patients with ALS. Amyotroph Lateral Scler 2007; 8: 362-365.
180. Raaphorst J, De Visser M, Linssen WH, et al. The cognitive profile of amyotrophic lateral sclerosis: a meta-analysis. Amyotroph Lateral Scler 2010; 11: 27-37.
181. Bak TH, Hodges JR. Motor neurone disease, dementia and aphasia. Coincidence, co-occurrence or continuum. J Neurol 2001; 248: 260-270.
182. Cobble M. Language impairment in motor neurone disease. J Neurol Sci 1998; 160(Suppl. 1): S47-S52.
183. Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurol Clin 2001; 19: 829-847.
184. Mitsumoto H, Bromberg M, Johnston W, et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 145-154.
185. Ganzini L, Johnston WS, McFarland BH, Tolle SW, Lee MA. Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide. N Engl J Med 1998; 339: 967-973.
186. Veldink JH, Wokke JH, van der Wal G, Vianney de Jong JM, van den Berg LH. Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 2002; 346: 1638-1644.